Skip to content

Hellenic Registry of Ovation Alto™ Abdominal Stent Graft System

Hellenic Registry of Subjects Receiving the Ovation Alto™ Abdominal Stent Graft System

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05172830
Enrollment
60
Registered
2021-12-29
Start date
2021-01-01
Completion date
2022-12-31
Last updated
2021-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Aortic Aneurysm

Keywords

EVAR, Endovascular aneurysm repair, Ovation Alto

Brief summary

This is a Hellenic Registry including both retrospective and prospective subjects receiving the Ovation Alto™ Abdominal Stent Graft System (Ovation Alto™ Abdominal Stent Graft System Post-Market Study) in the treatment of abdominal aortic aneurysms (AAA). The Ovation Alto™ Hellenic Registry is intended to expand the clinical knowledge base by collecting data on subjects treated with the Ovation Alto™ Abdominal Stent Graft System in actual clinical practice during the first post-operative year.

Interventions

DEVICEOvation Alto™ Abdominal Stent Graft System

Single occurrence permanent implantation of AAA device

Sponsors

University of Patras
CollaboratorOTHER
University Hospital of Crete
CollaboratorOTHER
University Hospital, Alexandroupolis
CollaboratorOTHER
Larissa University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject is \> 18 years of age * Both IFU and non-adherence to IFU * Subject intends to electively receive the Ovation Alto™ Abdominal Stent Graft System * Subject has the ability and willingness to comply with all follow-up exams as indicated in clinical investigation plan

Exclusion criteria

* Subject's current participation in a concurrent randomized control trial (RCT) or investigational device/drug study which could confound study results. * Life expectancy less than 1 year * Pregnancy * Subjects with poor renal function as indicated by a serum creatinine \> 2.5mg/dl.

Design outcomes

Primary

MeasureTime frameDescription
Treatment success12 monthsTreatment success is defined as technical success, freedom from type I and III endoleaks at 12 months, freedom from stent graft migration \> 10m at 12 months compared to 1 month baseline, freedom from AAA enlargement \>5mm at 12 months (compared to 1-month baseline, freedom from AAA rupture through 12 months, freedom from conversion to open repair through 12 months, stent graft stenosis, occlusion or kink requiring secondary intervention through 12 months, thromboembolic event attributable to stent graft requiring secondary intervention through 12 months, stent fracture requiring secondary intervention through 12 months.

Secondary

MeasureTime frameDescription
Stent Graft Migration1 and 12 monthsAny proximal caudal Stent Graft Migration \>10mm
Abdominal aortic aneurysm sac enlargement1 and 12 monthsAny sac enlargement \> 5mm
Aortic neck alteration1 and 12 monthsAny neck diameter increase at supra-renal part of the aorta (at 0mm, 10mm and 20mm above the highest renal artery), and infra-renal part of the aorta (at 0mm, 7mm, and 15mm below the lowest renal artery). Measurements of the aortic neck angulation will also be included
Freedom from abdominal aortic aneurysm rupture1 and 12 monthsRecording of any abdominal aortic aneurysm rupture that takes place during the follow up after the procedure in order to assess freedom from this adverse event
Number and Classification of Endoleaks1 and 12 monthsEndoleak type Ia and Ib and III
AAA-related mortality1 and 12 monthsAny aneurysm related mortality
Device-related Adverse Events (AEs)1 and 12 monthsDevice-related Adverse Events: loss of latency, stent fracture, migration, Endoleak type I and III
Major adverse events1 and 12 monthsIncluding death, myocardial infarction, stroke, chronic renal disease, stent graft infection, amputation
Adherence to instruction for use12 monthsRecording of patients in terms of adherence to instructions for use according to the device manual
Number of Secondary Interventions1 and 12 monthsAny secondary intervention stent-graft related including: proximal extension with a balloon expandable covered stent; stent graft extension distally to common iliac arteries; use of onyx for Endoleak Ia; bare metal stent in external iliac arteries

Countries

Greece

Contacts

Primary ContactKonstantinos Spanos, PhD
spanos.kon@gmail.com00306948570321
Backup ContactAthanasios Giannoukas, Prof
agiannoukas@hotmail.com00306944724146

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026